Pelareorep Plus Paclitaxel: A Significant Advancement in Oncology for HR+/HER2– Breast Cancer
The Promising Efficacy of Pelareorep and Paclitaxel in Cancer Treatment
The median overall survival (OS) was not reached with the combination of the oncolytic viral therapy pelareorep (Reolysin) plus paclitaxel for the treatment of patients with hormone receptor (HR)-positive/HER2-negative breast cancer, according to positive results from the phase 2 BRACELET-1 study (NCT04215146).
Final efficacy data from the randomized BRACELET-1 trial were collected and analyzed 2 years following the enrollment of the last patient, as specified by the protocol. In the pelareorep/paclitaxel arm, more than half of the patients remained alive at the end of the study compared with a median OS of 18.2 months in the paclitaxel monotherapy arm (HR, 0.48).
Long-term Projections for Survival
If the study follow-up had continued beyond the 2-year mark, and patients had only lived until their next planned visit in 4 months, the projected median OS in the pelareorep plus paclitaxel arm would have been 32.1 months.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.